Home
Storia in 3 fonti
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
- ·
morningstar.com
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across…
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
- ·
endpoints.news
After key trial fail, Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a deal with Parabilis Medicines valued at as much as…
- ·
pharmaceutical-technology.com
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on AHCs.